Anticoagulazione ed emodialisi cronica - Società Italiana di Nefrologia

Anticoagulazione ed emodialisi cronica
between platelets and leukocytes during hemodialysis.
Artif Organs 1999; 23: 23-8.
17. Gawaz MP, Mujais SK, Schmidt B, Blumenstein M,
Gurland HJ. Platelet-leukocyte aggregates during hemodialysis:
effect of membrane type. Artif Organs 1999; 23:
29-36.
18. Gorbet MB, Sefton MV. Leukocyte activation and leukocyte
procoagulant activities after blood contact with polystyrene
and polyethylene glycol-immobilized polystyrene
beads. J Lab Clin Med 2001; 137: 345-55.
19. Basmadjian D, Sefton MV, Baldwin SA. Coagulation on
biomaterials in flowing blood: some theoretical considerations.
Biomaterials 1997; 18: 1511-22.
20. Keuren JF, Wielders SJ, Willems GM, et al.
Thrombogenicity of polysaccharide-coated surfaces.
Biomaterials 2003; 24: 1917-24.
21. McClung WG, Clapper DL, Hu SP, Brash JL. Lysine-derivatized
polyurethane as a clot lysing surface: conversion of
adsorbed plasminogen to plasmin and clot lysis in vitro.
Biomaterials 2001; 22: 1919-24.
22. Frank RD, Müller U, Lanzmich R, Groeger C, Floege J.
Anticoagulant-free Genius® haemodialysis using low
molecular weight heparin-coated circuits. Nephrol Dial
Transplant 2006; 21: 1013-8.
23. Klingel R, Schaefer M, Schwarting A, et al. Comparative
analysis of procoagulatory activity of hemodialysis, haemofiltration
and haemodiafiltration with a polysulfone
membrane (APS) and with different modes of enoxaparin
anticoagulation. Nephrol Dial Transplant 2004; 19: 164-
70.
24. van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH,
Kingma WP, Boerma EC. Filter run time in CVVH: pre- versus
post-dilution and nadroparin versus regional heparinprotamine
anticoagulation. Blood Purif 2005; 23: 175-
80.
25. Frank RD, Weber J, Dresbach H, Thelen H, Weiss C,
Floege J. Role of contact system activation in haemodialyzer-induced
thrombogenicity. Kidney Int 2001; 60: 1972-
81.
26. Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer
M. Activation of the tissue factor pathway occurs during
continuous venovenous hemofiltration. Kidney Int 1999;
55: 1568-74.
27. Bick RL, Frenkel EP. Clinical aspects of heparin-induced
thrombocytopenia and thrombosis and other side effects
of heparin therapy. Clin Appl Thromb Hemost 1999; 5
(Suppl. 1): S7-15.
28. Fischer KG. Haemodialysis in heparin-induced thrombocytopenia.
In: Warkentin TE, Greinacher A, ed. Heparininduced
thrombocytopenia, New York: Marcel Dekker,
2004; 509-30.
29. European best practice guidelines for haemodialysis (part
1). Nephrol Dial Transplant 2002; 17 (Suppl. 7): 63-71.
30. Opatrny K Jr, Bouda M, Kohoutkova L, Vit L, Sefrna F. A
clinical study to assess the effect of heparin in dialyzer rinsing.
Int J Artif Organs 1997; 20: 112-8.
31. Ouseph R, Ward RA. Anticoagulation for intermittent
hemodialysis. Semin Dial 2000; 13: 181-7.
32. Teien AN, Bjoornson J. Heparin elimination in uraemic
patients on haemodialysis. Scand J Haematol 1976; 17:
29-35.
33. Taylor JE, Belch JJ, McLaren M, Henderson IS, Stewart
WK. Effect of erythropoietin therapy and withdrawal on
blood coagulation and fibrinolysis in hemodialysis
patients. Kidney Int 1993; 44: 182-90.
34. Clyne N, Lins LE, Egberg N. Long-term effects of erythropoietin
treatment on the coagulation system during standardized
hemodialysis. Clin Nephrol 1995; 43: 260-7.
35. Gretz N, Quintel M, Ragaller M, et al. Low-dose heparinization
for anticoagulation in intensive care patients on
394
continuous haemofiltration. Contrib Nephrol 1995; 116:
130-5.
36. Schultze G, Hollmann S, Sinah P. Formation of thrombinantithrombin
III complex using polyamide and haemophan
dialyzers. Int J Artif Organs 1992; 15: 370-3.
37. Wright MJ, Woodrow G, Umpleby S, Hull S, Brownjohn
AM, Turney JH. Low thrombogenicity of polyethylene
glycol-grafted cellulose membranes does not influence
heparin requirements in haemodialysis. Am J Kidney Dis
1999; 34: 36-42.
38. Lohr JW, Schwab SJ. Minimizing hemorrhagic complications
in dialysis patients. J Am Soc Nephrol 1991; 2: 961-
75.
39. Swartz RD, Port FK. Preventing hemorrhage in high-risk
hemodialysis: regional versus low-dose heparin. Kidney
Int 1979; 16: 513-8.
40. Sanders PW, Taylor H, Curtis JJ. Hemodialysis without
anticoagulation. Am J Kidney Dis 1985; 5: 32-5.
41. Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos
JG, Stathakis CP. Hemodialysis for patients bleeding or at
risk for bleeding, can be simple, safe and efficient. Clin
Nephrol 2004; 62: 29-34.
42. Schwab SJ, Onorato JJ, Sharar LR, Dennis, PA.
Hemodialysis without anticoagulation. One-year prospective
trial in hospitalized patients at risk for bleeding. Am J
Med 1987; 83: 405-10.
43. Gordon LA, Perkins HA, Richards V, Rukes JM, Simon ER.
Studies in regional heparinization. II. Artificial-kidney
hemodialysis without systemic heparinization; preliminary
report of a method using simultaneous infusion of heparin
and protamine. N Engl J Med 1956; 255: 1063-6.
44. Maher JF, Lapierre L, Schreiner GE, et al. Regional heparinization
for hemodialysis. N Engl J Med 1963; 268: 451.
45. Blaufox MD, Hampers CL, Merrill JP. Rebound anticoagulation
occurring after regional heparinization for hemodialysis.
Trans Am Soc Artif Intern Organs 1966; 12: 207-9.
46. Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate
anticoagulation for hemodialysis in the patient at high risk
for bleeding. N Engl J Med 1983; 308: 258-61.
47. Von Brecht JH, Flanigan MJ, Freeman RM, Lim VS.
Regional anticoagulation-hemodialysis with hypertonic
sodium tricitrate. Am J Kidney Dis 1986; 8: 196-201.
48. Janssen MJ, Huijgens PC, Bouman AA, Oe PL, Donker AJ,
van der Meulen J. Citrate versus heparin anticoagulation
in chronic haemodialysis patients. Nephrol Dial Transplant
1993; 8: 1228-33.
49. Flanigan MJ, Von Brecht JH, Freeman RM, Lim VS.
Reducing the hemorrhagic complications of dialysis: A
controlled comparison of low-dose heparin and citrate
anticoagulation. Am J Kidney Dis 1987; 9: 147-53.
50. Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G.
Citrate for long-term hemodialysis: Prospective study of
1,009 consecutive high-flux treatments in 59 patients. Am
J Kidney Dis 2005; 45: 557-64.
51. Swartz RD, Flamenbaum W, Dubrow A, Hall JC, Crow
JW, Cato A. Epoprostenol (PGI2 prostacyclin) during high
risk hemodialysis preventing further bleeding complications.
J Clin Pharmacol 1988; 28: 818-25.
52. Novacek G, Kapiotis S, Jilma B, et al. Enhanced blood
coagulation and enhanced fibrinolysis during haemodialysis
with prostacyclin. Thromb Res 1997; 88: 283-90.
53. Caruana RJ, Smith MC, Clyne D, Crow JW, Zin JM, Diehl
JH. Controlled study of heparin versus epoprostenol
sodium (prostacyclin) as the sole anticoagulant for chronic
hemodialysis. Blood Purif 1991; 9: 296-304.
54. Ota K, Kawaguchi H, Takahashi K, Ito K. A new prostacyclin
analog - an anticoagulant applicable to hemodialysis.
Trans Am Soc Artif Intern Organs 1983; 29: 419-
24.
55. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N,